Stock Analiz

KALA BIO, Inc. KALA

Biotechnology: Pharmaceutical Preparations · IPO 2017 · data as of November 13, 2026

$0.14Market cap $89479
Open the interactive analysis →

KALA BIO, Inc. (KALA) is a healthcare company listed in the US with a market value of about $89479.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is future growth (0/5).

Key numbers: 5-year revenue growth of -100% a year, a 5-year average ROIC of -159%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 494% above the current price.

About KALA BIO

KALA BIO is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2017. Revenue went from $45000 in 2015 to $4M in 2022, growth of about 89.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 436% over three years (dilution for shareholders).

Score: 1.0 / 5

Value1/5
Future growth0/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S—
P/B0.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price+494%

Growth and quality

Revenue growth (1 yr)—
Revenue growth (5 yrs, per year)-100.0%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-1210.2%
ROIC (5-yr avg.)-159.0%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$0$0$0$4M$11M$6M$6M—$0$0
Net income-$27M-$39M-$42M-$45M-$143M-$104M-$94M-$67M-$42M-$33M
Free cash flow——————-$94M-$56M-$35M-$28M
EPS (diluted)$-39.72$-121.80$-208.20$-353.76$-1299.84$-1182.72$-1640.35$-1479.88$-2204.97$-16682.88
Net margin———-1151.6%-1268.7%-1639.8%-1553.3%———
ROIC-442.2%-72.6%-71.5%-103.6%-104.9%-43.1%-65.7%-28.3%-28.9%—

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is KALA BIO stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 494% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does KALA BIO pay a dividend?

Not currently.

Is KALA BIO a good stock to buy?

We do not give buy or sell advice. KALA BIO scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.